What is NBIX's five-year median EV/EBITDA?

31.3x. Half of NBIX's weekly readings over the last five years were higher and half were lower. This page has 756 weekly readings, from Apr 30, 2012 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares NBIX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Neurocrine Biosciences Inc (NBIX) valuation history

Health Care

$142.70

Latest weekly close · Market cap $14.9B

Historically low

As of Oct 24, 2026

NBIX's EV/EBITDA of 17.2x is lower than 97% of its weekly readings over the last five years.

Weekly EV/EBITDA with its 5-year range

EV/EBITDA each weekMiddle half of the last 5 years5-year median 31.3×

5-year median: 31.3×
10-year median: 52.2×
5-year low to high: 14.0×–133.8×
Versus 5-year median: -45%

EV/EBITDA

3rdpercentile

of its weekly readings over the last five years

Historically low

Growth, last 12 months vs the year before

Revenue: +34%accelerating
EPS: +102%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

EV/EBITDA at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

NBIX EV/EBITDA at each year-end
Year-end	EV/EBITDA	5-year percentile
Dec 29, 2025	22.9×	16
Dec 30, 2024	21.8×	8
Dec 25, 2023	54.6×	22
Dec 26, 2022	89.3×	49
Dec 27, 2021	35.7×	3
Dec 28, 2020	56.8×	8
Dec 30, 2019	197.4×	24
Dec 31, 2018	217.6×	Too little history
Dec 25, 2017	n/a	Too little history
Dec 26, 2016	n/a	Too little history

Health Care peers on EV/EBITDA

Each percentile compares a stock with its own last five years.

Compare NBIX with peers

Health Care peers of NBIX on EV/EBITDA
Stock	EV/EBITDA	Versus its own history	5-year percentile
ABBVAbbVie	22.6×	Above its usual range	88
AMGNAmgen	20.3×	Historically high	96
ARWRArrowhead Pharmaceuticals Inc	n/a	Not ranked	n/a, not ranked
BBIOBridgebio Pharma Inc	n/a	Not ranked	n/a, not ranked
BIIBBiogen	20.3×	Historically high	100

Appears in

Sector: Health Care
Screens: Stocks with Low P/E Ratios and Steady Revenue Growth
Stocks Below Their 5-Year Median P/E
Stocks Near Their Lowest P/E Ratios in 5 Years

Screen Health Care stocks the same way

Research on NBIX

No articles about NBIX yet. How valuation percentiles work

Loading peers and related research…

About this history

What is NBIX's current EV/EBITDA?: NBIX's EV/EBITDA of 17.2x is lower than 97% of its weekly readings over the last five years.
What is NBIX's five-year median EV/EBITDA?: 31.3x. Half of NBIX's weekly readings over the last five years were higher and half were lower. This page has 756 weekly readings, from Apr 30, 2012 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares NBIX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.